Description
What is Vascepa (icosapent ethyl) for?
Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct therapy for adult patients with:
- elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or, diabetes mellitus and two or more additional risk factors for cardiovascular disease as an adjunct to maximally tolerated statin therapy.
- severe (≥ 500 mg/dL) hypertriglyceridemia as an adjunct to diet.
Where has Vascepa (icosapent ethyl) been approved?
Vascepa (icosapent ethyl) has been approved by:
- Food and Drug Administration (FDA), USA:
- On July 27, 2012 to reduce triglyceride levels in adults with severe hypertriglyceridemia
- On December 13, 2019 to reduce cardiovascular risk
- Health Canada on January 2, 2020 to reduce cardiovascular risk
- European Medicines Agency (EMA) on January 29, 2021 under the brand name Vazkepa to reduce cardiovascular risk
Reviews
There are no reviews yet.